- •KELIM score may be a marker of chemosensitivity in patients with ovarian cancer treated with neoadjuvant chemotherapy.
- •Patients with a KELIM<1 had a lower progression free- and overall survival compared to patients with KELIM ≥1.
- •Patients with KELIM<1 had higher risk of disease progression and death compared to patients with KELIM ≥1.
- •BRCA positive mutation status was independently associated with a higher KELIM score.
- •Patients with KELIM<1 were more likely to have platinum-resistant disease and worse progression free- and overall survival.
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- A comparison of survival outcomes in advanced serous ovarian Cancer patients treated with primary Debulking surgery versus neoadjuvant chemotherapy.Int. J. Gynecol. Cancer. 2017; 27: 668-674
- Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis.J. Clin. Oncol. 2002; 20: 1248-1259
- Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182.J. Clin. Oncol. 2015; 33: 937-943
- Examining survival outcomes of 852 women with advanced ovarian Cancer: a multi-institutional cohort study.Int. J. Gynecol. Cancer. 2018; 28: 925-931
- Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850).Int. J. Gynecol. Cancer. 2020; 30: 1657-1664
- Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial.Lancet (London, England). 2015; 386: 249-257
- Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer.Eur. J. Cancer. 2011; 47 (Oxford, England : 1990): S88-S92
- Characteristics and survival of ovarian cancer patients treated with neoadjuvant chemotherapy but not undergoing interval debulking surgery.J. Gynecol. Oncol. 2020; 31e17
- Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - an NRG oncology/gynecologic oncology group study.Gynecol. Oncol. 2017; 144: 459-467
- Outcome of patients with advanced ovarian cancer who do not undergo debulking surgery: a single institution retrospective review.Gynecol. Oncol. 2017; 144: 57-60
- Non-surgical management of ovarian cancer: prevalence and implications.Gynecol. Oncol. 2016; 142: 30-37
- Primary chemotherapy for inoperable ovarian, fallopian tube, or primary peritoneal cancer with or without delayed debulking surgery.Int. J. Gynecol. Cancer. 2012; 22: 566-572
- The prognostic value of perioperative, pre-systemic therapy CA125 levels in patients with high-grade serous ovarian cancer.Int. J. Gynaecol. Obstet. 2018; 140: 247-252
- CA-125 reduction during neoadjuvant chemotherapy is associated with success of cytoreductive surgery and outcome of patients with advanced high-grade ovarian cancer.Acta Obstet. Gynecol. Scand. 2020; 99: 933-940
- CA-125 ELIMination rate constant K (KELIM) is a marker of Chemosensitivity in patients with ovarian Cancer: results from the phase II CHIVA trial.Clin. Cancer Res. 2020; 26: 4625-4632
- The role of the tumor primary chemosensitivity relative to the success of the medical-surgical management in patients with advanced ovarian carcinomas.Cancer Treat. Rev. 2021; 102294
- Using an evidence-based triage algorithm to reduce 90-day mortality after primary debulking surgery for advanced epithelial ovarian cancer.Gynecol. Oncol. 2019; 155: 58-62
- Models to predict outcomes after primary debulking surgery: independent validation of models to predict suboptimal cytoreduction and gross residual disease.Gynecol. Oncol. 2019; 154: 72-76
- Functional not chronologic age: frailty index predicts outcomes in advanced ovarian cancer.Gynecol. Oncol. 2017; 147: 104-109
- Risk-prediction model of severe postoperative complications after primary debulking surgery for advanced ovarian cancer.Gynecol. Oncol. 2016; 140: 15-21
- Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer.Am. J. Obstet. Gynecol. 2007; 197: e1-e7
- A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study.Ann. Surg. Oncol. 2006; 13: 1156-1161
- Integrated Prediction Model of Patient Factors, Surgical Complexity and Surgical Resectability to Predict Outcome of Cytoreduction in Ovarian cancer.International Gynecologic Cancer Society Annual Global Meeting. Virtural, 2020
- Measurement tool of chemotherapy sensitivity in advanced ovarian Cancer.Clin. Cancer Res. 2020; 26: 4432-4434
Publication stageIn Press Corrected Proof
☆This study was presented as a poster presentation at the Society of Gynecologic Oncology Annual General Meeting, Phoenix, Arizona March 17–20, 2022 and the Gynecologic Oncology Society of Canada annual General meeting, virtual, June 10, 2022.